Las Vegas – September 19, 2026 -- The paroxysmal nocturnal hemoglobinuria (PNH) market across the seven major markets was valued at approximately $1.5 billion in 2025 and is projected to grow at a compound annual growth rate of 7.1% through 2036, according to DelveInsight.

South San Francisco, Calif. – September 19, 2026 -- Dualitas Therapeutics has secured a research collaboration and license agreement with Roche worth up to $1 billion, including a $36.5 million upfront payment, to develop bispecific antibody therapeutics for immunology and inflammation diseases.

Shanghai – September 19, 2026 -- WuXi XDC Cayman Inc. (2268.HK) has out-licensed its proprietary WuXiTecan-2 payload-linker technology platform to Ona Therapeutics under an exclusive global agreement targeting a single antibody-drug conjugate (ADC) candidate.

London – September 19, 2026 -- Clarivate Plc (NYSE: CLVT) named 22 researchers as its Citation Laureates 2026, identifying scientists whose work the company's Institute for Scientific Information (ISI) considers Nobel-class ahead of this year's Nobel Prize announcements. Since the program began in 2002, 89 previously named Citation Laureates have gone on to win Nobel Prizes.

Stockholm – September 19, 2026 -- Swedish Orphan Biovitrum AB (Sobi) has paid Innate Pharma SA USD 75 million as their strategic oncology partnership becomes legally effective, following the expiration of antitrust waiting periods and satisfaction of other closing conditions.

Santa Ana, Calif. – September 19, 2026 -- Robinson Pharma, Inc. (RPI) has received the "Above and Beyond" Supplier Award from Bausch + Lomb for September 2026, recognizing sustained operational performance following a $115 million infrastructure expansion.

Franklin, Tennessee – September 19, 2026 -- Adora Life Science has appointed Dr. Clinton D. Morgan, MD, as its full-time Chief Medical Officer, effective November 1, 2026, the company announced.

Québec City – September 19, 2026 -- Linearis Labs has secured funding for two projects under the Terry Fox Research Institute's (TFRI) Digital Health Innovation Fund, part of a combined $40.9 million investment spread across 14 pan-Canadian project teams and 55 partners.

New York – September 19, 2026 -- Medisights, an AI-native platform for life sciences, has completed a study showing purpose-built AI agents can compress months of qualitative physician research into days while tracking the fast-shifting multiple myeloma treatment landscape.

Jupiter, Florida – September 19, 2026 -- Myosin Therapeutics, Inc. has been selected as one of just 30 companies for the National Cancer Institute's 2026–2027 Investor Initiatives Showcase, a distinction drawn from NCI's full portfolio of funded companies following a competitive review by more than 70 third-party investors and strategic partners.